In cell therapy, trust isn’t optional — it’s foundational.
We’ve led 25 cell therapy studies across 15 indications — not just managing endpoints but building sponsor confidence throughout.
WHY BIORASI FOR CELL THERAPY?
Cell therapy trials come with increased scientific risk, logistical complexity, and high regulatory scrutiny. At Biorasi, our approach is built on transparency, careful coordination, and therapeutic familiarity — from protocol design through to long-term follow-up.
Subspecialties
- Stem Cell Therapies (Alzheimer’s, TBI, Parkinson’s)
- Cell therapy in rare neurodegenerative disorders
- Pediatric and FIH (first-in-human) applications
Proof of
Performance
- 25 Studies
- 15 Indications
- Delivered across Alzheimer’s, TBI, Parkinson’s, and others
Case Studies and Results
- Stem Cell Therapy Trial for TBI (Traumatic Brain Injury)
- 61 patients enrolled across 25 sites in 12 months
- Surpassed sponsor expectations
- Managed surgical complexity, high screen fail rates, and subjective endpoint variability
- Delivered on timeline and on budget
FROM OUR PARTNERS
Nataliya Agafonova, MD
Chief Medical Officer,, Longeveron Inc.
“As a small biotech company, quality within tight timelines is essential — and Biorasi delivered. Their support across clinical operations, biostatistics, and medical writing was outstanding.”